Accéder au contenu
Merck

RNF4~RGMb~BMP6 axis required for osteogenic differentiation and cancer cell survival.

Cell death & disease (2022-09-25)
Rostislav Novak, Yamen Abu Ahmad, Michael Timaner, Eliya Bitman-Lotan, Avital Oknin-Vaisman, Roi Horwitz, Oliver Hartmann, Michaela Reissland, Viktoria Buck, Mathias Rosenfeldt, David Nikomarov, Markus Elmar Diefenbacher, Yuval Shaked, Amir Orian
RÉSUMÉ

Molecular understanding of osteogenic differentiation (OD) of human bone marrow-derived mesenchymal stem cells (hBMSCs) is important for regenerative medicine and has direct implications for cancer. We report that the RNF4 ubiquitin ligase is essential for OD of hBMSCs, and that RNF4-deficient hBMSCs remain as stalled progenitors. Remarkably, incubation of RNF4-deficient hBMSCs in conditioned media of differentiating hBMSCs restored OD. Transcriptional analysis of RNF4-dependent gene signatures identified two secreted factors that act downstream of RNF4 promoting OD: (1) BMP6 and (2) the BMP6 co-receptor, RGMb (Dragon). Indeed, knockdown of either RGMb or BMP6 in hBMSCs halted OD, while only the combined co-addition of purified RGMb and BMP6 proteins to RNF4-deficient hBMSCs fully restored OD. Moreover, we found that the RNF4-RGMb-BMP6 axis is essential for survival and tumorigenicity of osteosarcoma and therapy-resistant melanoma cells. Importantly, patient-derived sarcomas such as osteosarcoma, Ewing sarcoma, liposarcomas, and leiomyosarcomas exhibit high levels of RNF4 and BMP6, which are associated with reduced patient survival. Overall, we discovered that the RNF4~BMP6~RGMb axis is required for both OD and tumorigenesis.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-BMP6 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody